Thromboxane A2: Physiology/pathophysiology, cellular signal transduction and pharmacology

Pharmacology and Therapeutics

Volumn 118, Issue 1, 2008, Pages 18-35

  Nakahata, Norimichi ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

G proteins; signal transduction; Thromboxane A2; Thromboxane A2 receptor (TP); Thromboxane synthase

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 3 [4 (3 PYRIDYLMETHYL)PHENYL]METHACRYLIC ACID; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4,5 DIHYDRO 2 (1H IMIDAZOL 1 YLMETHYL) 6 BENZO[B]THIOPHENECARBOXYLIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; DALTROBAN; DAZMEGREL; DAZOXIBEN; EPIDERMAL GROWTH FACTOR; FLAVANOID; FUREGRELATE; GUANINE NUCLEOTIDE BINDING PROTEIN; IFETROBAN; ISBOGREL; ISOPROTEIN; LINOTROBAN; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; OZAGREL; PIRMAGREL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTAGLANDIN SYNTHASE INHIBITOR; SULOTROBAN; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; THROMBOXANE A2 RECEPTOR STIMULATING AGENT; THROMBOXANE SYNTHASE INHIBITOR; UNINDEXED DRUG; VAPIPROST; ENZYME INHIBITOR;

ALLERGY; ANGIOGENESIS; ASTHMA; ATHEROSCLEROSIS; CELL DIFFERENTIATION; CELL MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; DESENSITIZATION; DIMERIZATION; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; ENZYME ACTIVATION; HUMAN; INFLAMMATION; LIGAND BINDING; METASTASIS; NONHUMAN; OLIGOMERIZATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTION; SPECIES DIFFERENCE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOGENESIS; TISSUE DISTRIBUTION; TRANSACTIVATION; ANIMAL; BIOSYNTHESIS; DRUG ANTAGONISM; METABOLISM;

ANIMALS; CYCLOOXYGENASE INHIBITORS; ENZYME INHIBITORS; GTP-BINDING PROTEINS; HUMANS; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; SIGNAL TRANSDUCTION; THROMBOXANE A2;

EID: 42649113385     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2008.01.001     Document Type: Review

References (207)

1. Abe T., Takeuchi K., Takahashi N., Tsutsumi E., Taniyama Y., and Abe K. Rat kidney thromboxane receptor: molecular cloning, signal transduction, and intrarenal expression localization. J Clin Invest 96 (1995) 657-664
2. Ahn S., Nelson C.D., Garrison T.R., Miller W.E., and Lefkowitz R.J. Desensitization, internalization, and signaling functions of β-arrestins demonstrated by RNA interference. Proc Natl Acad Sci U S A 100 (2003) 1740-1744
3. 2 in blood vessel walls and its physiological significance: relevance to thrombosis and hypertension. Prostaglandins Med 4 (1980) 431-438
4. Aoki N., Johnson III G., Siegfried M.R., and Lefer A.M. Protective effects of a combination thromboxane synthesis inhibitor-receptor antagonist, R-68070, during murine traumatic shock. Eicosanoids 2 (1989) 169-174
5. Arakida Y., Ohga K., Suwa K., Yokota M., Miyata K., Yamada T., et al. Effects of lipid mediator antagonists on predominant mediator-controlled asthmatic reactions in passively sensitized guinea pigs. J Pharmacol Exp Ther 290 (1999) 1285-1291
6. 2 receptors. J Pharmacol Exp Ther 287 (1998) 633-639
7. Armstrong R.A., and Wilson N.H. Aspects of the thromboxane receptor system. Gen Pharmacol 26 (1995) 463-472
8. Armstrong R.A., Jones R.L., and Wilson N.H. Ligand binding to thromboxane receptors on human platelets: Correlation with biological activity. Br J Pharmacol 79 (1983) 953-964
9. Arora K.K., Krsmanovic L.Z., Mores N., O'Farrell H., and Catt K.J. Mediation of cyclic AMP signaling by the first intracellular loop of the gonadotropin-releasing hormone receptor. J Biol Chem 273 (1998) 25581-25586
10. Ashida Y., Matsumoto T., Kuriki H., Shiraishi M., Kato K., and Terao S. A novel anti-asthmatic quinone derivative, AA-2414 with a potent antagonistic activity against a variety of spasmogenic prostanoids. Prostaglandins 38 (1989) 91-112
11. 2 receptor signaling inhibits vascular endothelial growth factor-induced endothelial cell differentiation and migration. Circ Res 95 (2004) 372-379
12. Ashton A.W., Ware G.M., Kaul D.K., and Ware J.A. Inhibition of tumor necrosis factor alpha-mediated NFκB activation and leukocyte adhesion, with enhanced endothelial apoptosis, by G protein-linked receptor (TP) ligands. J Biol Chem 278 (2003) 11858-11866
13. 2 receptor gene. Biochem Biophys Res Commun 256 (1999) 391-397
14. Berridge M.J., and Irvine R.F. Inositol trisphosphate, a novel second messenger in cellular signal transduction. Nature 312 (1984) 315-321
15. Bitterman H., Yanagisawa A., and Lefer A.M. Beneficial actions of thromboxane receptor antagonism in hemorrhagic shock. Circ Shock 20 (1986) 1-11
16. 2 receptors. J Biol Chem 273 (1998) 475-483
17. 2 receptors by immunoaffinity chromatography employing anti-peptide and anti-receptor antibodies. J Biol Chem 269 (1994) 6109-6116
18. 2 receptor in the rat kidney. Kidney Int 49 (1996) 1207-1213
19. Brown G.P., and Venuto R.C. Thromboxane receptors in human kidney tissues. Prostaglandins Other Lipid Mediat 57 (1999) 179-188
20. Bruggeman L.A., Horigan E.A., Horikoshi S., Ray P.E., and Klotman P.E. Thromboxane stimulates synthesis of extracellular matrix proteins in vitro. Am J Physiol 261 (1991) F488-F494
21. 2 receptor: alternative role in G protein-coupled receptor signaling. Mol Pharmacol 66 (2004) 880-889
22. 2 receptors and the corresponding mRNAs in human eye tissue. Br J Ophthalmol 78 (1994) 921-926
23. 2 receptor in ligand binding. Arch Biochem Biophys 352 (1998) 207-213
24. 2 receptor in insect cells. Arch Biochem Biophys 334 (1996) 9-17
25. Coker S.J. Further evidence that thromboxane exacerbates arrhythmias: Effects of UK38485 during coronary artery occlusion and reperfusion in anaesthetized greyhounds. J Mol Cell Cardiol 16 (1984) 633-641
26. 2 receptor from K562 (human chronic myelogenous leukemia) cells. J Pharmacol Exp Ther 271 (1994) 1034-1041
27. 2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 59 (1999) 4574-4577
28. 2 and related prostaglandins in airways. Fundam Clin Pharmacol 11 (1997) 2-18
29. 2 inhibition: therapeutic potential in bronchial asthma. Am J Respir Med 1 (2002) 11-17
30. Dogne J.M., Hanson J., de Leval X., Masereel B., Kolh P., and Pirotte B. New developments on thromboxane modulators. Mini Rev Med Chem 4 (2004) 649-657
31. Dogne J.M., Hanson J., de Leval X., Pratico D., Pace-Asciak C.R., Drion P., et al. From the design to the clinical application of thromboxane modulators. Curr Pharm Des 12 (2006) 903-923
32. Dogne J.M., Hanson J., and Pratico D. Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis. Trends Pharmacol Sci 26 (2005) 639-644
33. Dogne J.M., Rolin S., de Leval X., Benoit P., Neven P., Delarge J., et al. Pharmacology of the thromboxane receptor antagonist and thromboxane synthase inhibitor BM-531. Cardiovasc Drug Rev 19 (2001) 87-96
34. 2 in CHRF-288 megakaryocytic cells. Am J Physiol 262 (1992) C991-C999
35. 2 receptors. Am J Physiol 260 (1991) H327-H334
36. Dorn II G.W., Davis M.G., and D'Angelo D.D. Structural determinants for agonist binding affinity to thromboxane/prostaglandin endoperoxide (TP) receptors. Analysis of chimeric rat/human TP receptors. J Biol Chem 272 (1997) 12399-12405
37. 2 receptors in patients with acute myocardial infarction. Circulation 81 (1990) 212-218
38. Eikelboom J.W., Hirsh J., Weitz J.I., Johnston M., Yi Q., and Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105 (2002) 1650-1655
39. h (transglutaminase II)-mediated signaling. J Biol Chem 271 (1996) 16451-16454
40. Fennekohl A., Schieferdecker H.L., Jungermann K., and Puschel G.P. Differential expression of prostanoid receptors in hepatocytes, Kupffer cells, sinusoidal endothelial cells and stellate cells of rat liver. J Hepatol 30 (1999) 38-47
41. Feuerstein N., and Ramwell P.W. OKY-1581, a potential selective thromboxane synthetase inhibitor. Eur J Pharmacol 69 (1981) 533-534
42. 2-induced bronchoconstriction in the guinea-pig. Br J Pharmacol 104 (1991) 596-602
43. 2 receptor allows discrimination between agonist and antagonist binding sites. Mol Pharmacol 44 (1993) 934-939
44. 2-dependent extracellular-signal-regulated kinase activation. Biochem J 371 (2003) 733-742
45. i coupling and Src-dependent phosphorylation of the epidermal growth factor receptor. J Pharmacol Exp Ther 296 (2001) 426-433
46. 2 receptor. Arch Biochem Biophys 423 (2004) 253-265
47. 2 receptor blockade in genetically hypertensive rats of the Lyon strain. J Hypertens Suppl 7 (1989) S272-S273
48. 2 receptor antagonist in human platelets. Thromb Haemost 61 (1989) 479-484
49. 2 receptor. J Thromb Haemost 3 (2005) 369-376
50. Guth B.D., and Muller T.H. DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs. Basic Res Cardiol 92 (1997) 181-190
51. Habib A., FitzGerald G.A., and Maclouf J. Phosphorylation of the thromboxane receptor α, the predominant isoform expressed in human platelets. J Biol Chem 274 (1999) 2645-2651
52. Hall A. Rho GTPases and the actin cytoskeleton. Science 279 (1998) 509-514
53. 2 receptors: Where have you gone?. Prostaglandins Other Lipid Mediat 60 (2000) 175-189
54. Hamberg M., Svensson J., and Samuelsson B. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A 72 (1975) 2994-2998
55. Hamelin E., Theriault C., Laroche G., and Parent J.L. The intracellular trafficking of the G protein-coupled receptor TPβ depends on a direct interaction with Rab11. J Biol Chem 280 (2005) 36195-36205
56. Hamm C.W., Lorenz R.L., Bleifeld W., Kupper W., Wober W., and Weber P.C. Biochemical evidence of platelet activation in patients with persistent unstable angina. J Am Coll Cardiol 10 (1987) 998-1006
57. 2 receptor antagonist in platelets. Thromb Res 50 (1988) 365-376
58. 2 to actin polymerization and apoptosis in thymocytes. Eur J Immunol 35 (2005) 1977-1986
59. Hata A.N., and Breyer R.M. Pharmacology and signaling of prostaglandin receptors: Multiple roles in inflammation and immune modulation. Pharmacol Ther 103 (2004) 147-166
60. Haurand M., and Ullrich V. Isolation and characterization of thromboxane synthase from human platelets as a cytochrome P-450 enzyme. J Biol Chem 260 (1985) 15059-15067
61. 2 receptors in human placenta. Am J Physiol 256 (1989) E256-E263
62. 2 synthetase inhibitor (E)-3-[p-(1H-imidazol-1-ylmethyl)phenyl]-2-propenoic acid (OKY-046). Jpn J Pharmacol 41 (1986) 393-401
63. 2 receptor. Nature 349 (1991) 617-620
64. 2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation. J Clin Invest 97 (1996) 949-956
65. 12/13-dependent glial morphological change. Eur J Pharmacol 545 (2006) 100-108
66. Houslay M.D., Bojanic D., and Wilson A. Platelet activating factor and U44069 stimulate a GTPase activity in human platelets which is distinct from the guanine nucleotide regulatory proteins, Ns and Ni. Biochem J 234 (1986) 737-740
67. Huang J.S., Dong L., and Le Breton G.C. Mass-dependent signaling between G protein coupled receptors. Cell Signal 18 (2006) 564-576
68. Hunt J.A., Merritt J.E., MacDermot J., and Keen M. Characterization of the thromboxane receptor mediating prostacyclin release from cultured endothelial cells. Biochem Pharmacol 43 (1992) 1747-1752
69. 2) receptor agonist enhances ICAM-1, VCAM-1 or ELAM-1 expression by human vascular endothelial cells. Clin Exp Immunol 112 (1998) 464-470
70. 2 receptor blockade suppresses intercellular adhesion molecule-1 expression by stimulated vascular endothelial cells. Eur J Pharmacol 312 (1996) 367-377
71. 2 receptor antagonist. Eur J Pharmacol 570 (2007) 38-42
72. 2 modulates interaction of dendritic cells and T cells and regulates acquired immunity. Nat Immunol 4 (2003) 694-701
73. 2 mimetic, U46,619, on pulmonary vagal afferents in the cat. Respir Physiol 87 (1992) 383-396
74. 1 receptor antagonist losartan. Br J Pharmacol 134 (2001) 1385-1392
75. 2 receptor. Biochim Biophys Acta 1621 (2003) 192-203
76. 2 receptor. Br J Pharmacol 142 (2004) 203-221
77. 2 receptor. Biochim Biophys Acta 1761 (2006) 1114-1131
78. 2. Brain Res 744 (1997) 175-178
79. 2 receptor protein. J Biol Chem 281 (2006) 26951-26965
80. 2α. J Pharmacol Exp Ther 281 (1997) 957-964
81. 2 receptor from rat astrocytes. Biochim Biophys Acta 1265 (1995) 220-223
82. Kitiyakara C., Welch W.J., Verbalis J.G., and Wilcox C.S. Role of thromboxane receptors in the dipsogenic response to central angiotensin II. Am J Physiol Regul Integr Comp Physiol 282 (2002) R865-R869
83. 2 receptors. J Biol Chem 268 (1993) 26011-26017
84. 2 stimulation in patients with nephrotic syndrome of childhood. Nephron 77 (1997) 309-314
85. 2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 114 (2004) 784-794
86. 2 receptors using SQB, a novel biotinylated receptor probe. Biochem Pharmacol 52 (1996) 763-770
87. 13. Science 280 (1998) 2109-2111
88. Ku E.C., McPherson S.E., Signor C., Chertock H., and Cash W.D. Characterization of imidazo[1,5-α]pyridine-5-hexanoic acid (CGS 13080) as a selective thromboxane synthetase inhibitor using in vitro and in vivo biochemical models. Biochem Biophys Res Commun 112 (1983) 899-906
89. 2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate. Arzneimittelforschung 44 (1994) 1196-1202
90. 2 receptor: relevance to receptor signaling and endocytosis. Cell Signal 17 (2005) 1373-1383
91. 2: overcoming of actin disruption by arrestin-3 but not arrestin-2. J Biol Chem 280 (2005) 23215-23224
92. Le Breton G.C., Venton D.L., Enke S.E., and Halushka P.V. 13-Azaprostanoic acid: a specific antagonist of the human blood platelet thromboxane/endoperoxide receptor. Proc Natl Acad Sci U S A 76 (1979) 4097-4101
93. LeDuc L.E., Wyche A.A., Sprecher H., Sankarappe S.K., and Needleman P. Analogues of arachidonic acid used to evaluate structural determinants of prostaglandin receptor and enzyme specificities. Mol Pharmacol 19 (1981) 242-247
94. 2. Proc Natl Acad Sci U S A 77 (1980) 1706-1710
95. Li Y., Kang J.X., and Leaf A. Differential effects of various eicosanoids on the production or prevention of arrhythmias in cultured neonatal rat cardiac myocytes. Prostaglandins 54 (1997) 511-530
96. 2 receptors in patients with pregnancy induced hypertension. Thromb Res 70 (1993) 205-210
97. 2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro. Br J Pharmacol 97 (1989) 783-794
98. Luttrell L.M., Della Rocca G.J., van Biesen T., Luttrell D.K., and Lefkowitz R.J. Gβγ subunits mediate Src-dependent phosphorylation of the epidermal growth factor receptor. A scaffold for G protein-coupled receptor-mediated Ras activation. J Biol Chem 272 (1997) 4637-4644
99. Maier U., Babich A., Macrez N., Leopoldt D., Gierschik P., Illenberger D., et al. Gβ5γ2 is a highly selective activator of phospholipid-dependent enzymes. J Biol Chem 275 (2000) 13746-13754
100. Martin W. The combined role of atheroma, cholesterol, platelets, the endothelium and fibrin in heart attacks and strokes. Med Hypotheses 15 (1984) 305-322
101. Martin C., Uhlig S., and Ullrich V. Cytokine-induced bronchoconstriction in precision-cut lung slices is dependent upon cyclooxygenase-2 and thromboxane receptor activation. Am J Respir Cell Mol Biol 24 (2001) 139-145
102. 2 receptors. J Pharmacol Exp Ther 250 (1989) 923-927
103. 2biosynthesis in atherosclerosis. Proc Natl Acad Sci U S A 85 (1988) 4511-4515
104. 2. Am J Physiol 260 (1991) C159-C166
105. Michaux C., Rolin S., Dogne J.M., Durant F., Masereel B., Delarge J., et al. Structure determination and comparison of BM567, a sulfonylurea, with terbogrel, two compounds with dual action, thromboxane receptor antagonism and thromboxane synthase inhibition. Bioorg Med Chem Lett 11 (2001) 1019-1022
106. 2 receptor activation mediates angiotensin II-induced postischemic neovascularization. Arterioscler Thromb Vasc Biol 26 (2006) 488-493
107. 2 receptor (TP) α and β isoforms. Biochim Biophys Acta 1425 (1998) 543-559
108. 2 receptor mediated activation of the mitogen activated protein kinase cascades in human uterine smooth muscle cells. Biochim Biophys Acta 1539 (2001) 147-162
109. 2 production from Kupffer cells of the prefibrotic rat liver. J Hepatol 46 (2007) 276-285
110. Minami K., and Kamei C. A chronic model for evaluating the itching associated with allergic conjunctivitis in rats. Int Immunopharmacol 4 (2004) 101-108
111. 2 in human platelets. Biochem J 400 (2006) 127-134
112. 2 receptor isoforms. Biol Pharm Bull 29 (2006) 719-724
113. 13. Implications for collagen-induced platelet activation. J Biol Chem 279 (2004) 45354-45359
114. Montuschi P., Barnes P.J., and Roberts II L.J. Isoprostanes: Markers and mediators of oxidative stress. FASEB J 18 (2004) 1791-1800
115. 2-stimulated mitogenesis of coronary artery smooth muscle cells involves activation of mitogen-activated protein kinase and S6 kinase. J Biol Chem 269 (1994) 5693-5698
116. 2 receptor: molecular cloning, expression, and functional characterization. Naunyn Schmiedebergs Arch Pharmacol 357 (1998) 10-16
117. Muck S., Weber A.A., and Schror K. Effects of terbogrel on platelet function and prostaglandin endoperoxide transfer. Eur J Pharmacol 344 (1998) 45-48
118. 2 receptors in Schwann cells. J Neurochem 78 (2001) 446-456
119. 2 is involved in the nitric oxide-induced central activation of adrenomedullary outflow in rats. Neuroscience 87 (1998) 197-205
120. 2 receptor desensitization. Cross-talk with adenylate cyclase in human platelets. J Biol Chem 265 (1990) 21670-21675
121. Nagai H., Teramachi H., and Tuchiya T. Recent advances in the development of anti-allergic drugs. Allergol Intern 55 (2006) 35-42
122. 2 receptors in cultured astrocytes from rabbit brain. Brain Res 583 (1992) 100-104
123. 2 activates phospholipase C in astrocytoma cells via pertussis toxin-insensitive G-protein. Eur J Pharmacol 162 (1989) 407-417
124. 2 receptors in human astrocytoma cells, rabbit astrocytes and human platelets. Res Commun Mol Pathol Pharmacol 87 (1995) 243-251
125. 2-mediated human platelet responses. Mol Pharmacol 39 (1991) 475-480
126. Namba T., Sugimoto Y., Hirata M., Hayashi Y., Honda A., Watabe A., et al. Mouse thromboxane A2 receptor: cDNA cloning, expression and northern blot analysis. Biochem Biophys Res Commun 184 (1992) 1197-1203
127. Narumiya S., Hirata N., Namba T., Hayashi Y., Ushikubi F., Sugimoto Y., et al. Structure and function of prostanoid receptors. J Lipid Mediat 6 (1993) 155-161
128. Needleman P., Minkes M., and Raz A. Thromboxanes: selective biosynthesis and distinct biological properties. Science 193 (1976) 163-165
129. 2 from prostaglandin endoperoxides. Nature 261 (1976) 558-560
130. 2 regulation of endothelial cell migration, angiogenesis, and tumor metastasis. Biochem Biophys Res Commun 267 (2000) 245-251
131. 2 receptors on human platelets. FEBS Lett 316 (1993) 99-102
132. Nishizuka Y. Turnover of inositol phospholipids and signal transduction. Science 225 (1984) 1365-1370
133. Nusing R.M., Hirata M., Kakizuka A., Eki T., Ozawa K., and Narumiya S. Characterization and chromosomal mapping of the human thromboxane A2 receptor gene. J Biol Chem 268 (1993) 25253-25259
134. O'Dowd B.F., Hnatowich M., Regan J.W., Leader W.M., Caron M.G., and Lefkowitz R.J. Site-directed mutagenesis of the cytoplasmic domains of the human β2-adrenergic receptor. Localization of regions involved in G protein-receptor coupling. J Biol Chem 263 (1988) 15985-15992
135. 2 promotes interleukin-6 biosynthesis mediated by an activation of cyclic AMP-response element-binding protein in 1321N1 human astrocytoma cells. Mol Pharmacol 68 (2005) 670-679
136. 16 couple a wide variety of receptors to phospholipase C. J Biol Chem 270 (1995) 15175-15180
137. 2 and thrombin receptors in human platelets. Proc Natl Acad Sci U S A 91 (1994) 504-508
138. 2. Fed Proc 46 (1987) 133-138
139. Ogletree M.L., Harris D.N., Greenberg R., Haslanger M.F., and Nakane M. Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist. J Pharmacol Exp Ther 234 (1985) 435-441
140. 2 stimulates mitogen-activated protein kinase and arachidonic acid liberation in rabbit platelets. Prostaglandins 52 (1996) 403-413
141. 2+ pathway in rabbit platelets. Br J Pharmacol 117 (1996) 1095-1104
142. 2 in the release of noradrenaline and adrenaline from adrenal medulla in rats. Eur J Pharmacol 467 (2003) 125-131
143. 2 synthetase, on eicosanoid production. Eur J Pharmacol 422 (2001) 209-216
144. 2 but not by serotonin. Respir Physiol 80 (1990) 203-217
145. Palea S., Toson G., Pietra C., Trist D.G., Artibani W., Romano O., et al. Pharmacological characterization of thromboxane and prostanoid receptors in human isolated urinary bladder. Br J Pharmacol 124 (1998) 865-872
146. Palmer M.A., Piper P.J., and Vane J.R. The release of rabbit aorta contracting substance (RCS) from chopped lung and its antagonism by anti-inflammatory drugs. Br J Pharmacol 40 (1970) 581P-582P
147. 2 receptor α and β isoforms. Role of the differentially spliced cooh terminus in agonist-promoted receptor internalization. J Biol Chem 274 (1999) 8941-8948
148. Patrignani P., Filabozzi P., and Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 69 (1982) 1366-1372
149. Patscheke H., and Stegmeier K. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets. Thromb Res 33 (1984) 277-288
150. 2 receptor. J Biol Chem 269 (1994) 19256-19261
151. 2 receptor is a target for nitric oxide-mediated desensitization. Independent modulation of TPα signaling by nitric oxide and prostacyclin. J Biol Chem 278 (2003) 51190-51202
152. 2 receptor. Modulation of G protein: effector coupling and modes of receptor internalization. Cell Signal 19 (2007) 1056-1070
153. 2 receptor antagonist with antithrombotic activity in humans at arterial blood flow conditions. Thromb Haemost 71 (1994) 103-109
154. Rochdi M.D., Laroche G., Dupre E., Giguere P., Lebel A., Watier V., et al. Nm23-H2 interacts with a G protein-coupled receptor to regulate its endocytosis through an Rac1-dependent mechanism. J Biol Chem 279 (2004) 18981-18989
155. 2 receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles. Prostaglandins Leukot Essent Fat Acids 65 (2001) 67-72
156. Rosentreter U., Boshagen H., Seuter F., Perzborn E., and Fiedler V.B. Synthesis and absolute configuration of the new thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazolepropan oic acid and comparison with its enantiomer. Arzneimittelforschung 39 (1989) 1519-1521
157. 2 receptor in 1321N1 human astrocytoma cells. J Pharmacol Exp Ther 276 (1996) 829-836
158. 1α in hand veins from patients with deep venous thrombosis. Thromb Res 32 (1983) 461-467
159. 2 receptor dimerization. J Pharmacol Sci 100 (2006) 263-270
160. 2 receptor beta-isoform through the negative regulation of its membrane traffic by proteasomes. Prostaglandins Other Lipid Mediat 83 (2007) 237-249
161. 2 pathway. Zentralbl Veterinarmed A 46 (1999) 123-131
162. Schumacher W.A., Steinbacher T.E., Youssef S., and Ogletree M.L. Antiplatelet activity of the long-acting thromboxane receptor antagonist BMS 180,291 in monkeys. Prostaglandins 44 (1992) 389-397
163. Shen R.F., and Tai H.H. Monoclonal antibodies to thromboxane synthase from porcine lung. Production and application to development of a tandem immunoradiometric assay. J Biol Chem 261 (1986) 11585-11591
164. Shen R.F., and Tai H.H. Thromboxanes: synthase and receptors. J Biomed Sci 5 (1998) 153-172
165. q family. J Biol Chem 266 (1991) 9309-9313
166. 2 synthetase inhibitor. Eur J Pharmacol 109 (1985) 135-144
167. 2 receptor in human nasal mucosa. Prostaglandins Leukot Essent Fat Acids 76 (2007) 315-320
168. 2 receptor in the second extracellular loop using the NMR experiment-guided mutagenesis approach. J Biol Chem 278 (2003) 10922-10927
169. Spurney R.F., Bernstein R.J., Ruiz P., Pisetsky D.S., and Coffman T.M. Physiologic role for enhanced renal thromboxane production in murine lupus nephritis. Prostaglandins 42 (1991) 15-28
170. Spurney R.F., Fan P.Y., Ruiz P., Sanfilippo F., Pisetsky D.S., and Coffman T.M. Thromboxane receptor blockade reduces renal injury in murine lupus nephritis. Kidney Int 41 (1992) 973-982
171. Spurney R.F., Onorato J.J., Albers F.J., and Coffman T.M. Thromboxane binding and signal transduction in rat glomerular mesangial cells. Am J Physiol 264 (1993) F292-F299
172. Stahl G.L., Darius H., and Lefer A.M. Antagonism of thromboxane actions in the isolated perfused rat heart. Life Sci 38 (1986) 2037-2041
173. Studer R.K., Negrete H., Craven P.A., and DeRubertis F.R. Protein kinase C signals thromboxane induced increases in fibronectin synthesis and TGF-β bioactivity in mesangial cells. Kidney Int 48 (1995) 422-430
174. Sun F.F., Chapman J.P., and McGuire J.C. Metabolism of prostaglandin endoperoxide in animal tissues. Prostaglandins 14 (1977) 1055-1074
175. 2 receptor. Prostaglandins Leukot Essent Fat Acids 71 (2004) 375-382
176. 3H]ONO NT-126. Res Commun Chem Pathol Pharmacol 76 (1992) 155-170
177. 2α mediate inflammatory tachycardia. Nat Med 11 (2005) 562-566
178. Tanaka T., Ito S., Higashino R., Fukuta Y., Fukuda Y., Takei M., et al. A new thromboxane receptor antagonist, Z-335, ameliorates experimental thrombosis without prolonging the rat tail bleeding time. Thromb Res 91 (1998) 229-235
179. 2 and IL-4 in atopic dermatitis. Biochem Biophys Res Commun 292 (2002) 776-780
180. Terrillon S., and Bouvier M. Roles of G-protein-coupled receptor dimerization. EMBO Rep 5 (2004) 30-34
181. 2 receptor (TPβ). Biochemistry 43 (2004) 5600-5607
182. 2 synthetase inhibitor in a canine coronary occlusion-reperfusion model. Arzneimittelforschung 38 (1988) 224-227
183. 2 receptor protein. J Biol Chem 277 (2002) 16791-16797
184. Uchida Y., and Murao S. Effects of thromboxane synthetase inhibitors on cyclical reduction of coronary blood flow in dogs. Jpn Heart J 22 (1981) 971-975
185. 2 receptor is highly expressed in mouse immature thymocytes and mediates DNA fragmentation and apoptosis. J Exp Med 178 (1993) 1825-1830
186. 2 receptor from human blood platelets. J Biol Chem 264 (1989) 16496-16501
187. i2 in phospholipid vesicles. Mol Pharmacol 46 (1994) 808-816
188. Vermylen J., Defreyn G., Carreras L.O., Machin S.J., Van Schaeren J., and Verstraete M. Thromboxane synthetase inhibition as antithrombotic strategy. Lancet 1 (1981) 1073-1075
189. h. J Biol Chem 274 (1999) 12774-12779
190. Vignola A.M., Mirabella F., Costanzo G., Di Giorgi R., Gjomarkaj M., Bellia V., et al. Airway remodeling in asthma. Chest 123 (2003) 417S-422S
191. 13 stimulates Na-H exchange. J Biol Chem 269 (1994) 4721-4724
192. 2 receptor alpha and beta isoforms. J Pharmacol Exp Ther 286 (1998) 1026-1036
193. 2 receptor is a target for prostacyclin-mediated desensitization. J Biol Chem 275 (2000) 20412-20423
194. 2 have potent and differentiated actions on human uterine contractility. Prostaglandins 21 (1981) 277-286
195. Wilson S.J., Dowling J.K., Zhao L., Carnish E., and Smyth E.M. Regulation of thromboxane receptor trafficking through the prostacyclin receptor in vascular smooth muscle cells: role of receptor heterodimerization. Arterioscler Thromb Vasc Biol 27 (2007) 290-296
196. Wilson S.J., McGinley K., Huang A.J., and Smyth E.M. Heterodimerization of the α and β isoforms of the human thromboxane receptor enhances isoprostane signaling. Biochem Biophys Res Commun 352 (2007) 397-403
197. Wilson S.J., Roche A.M., Kostetskaia E., and Smyth E.M. Dimerization of the human receptors for prostacyclin and thromboxane facilitates thromboxane receptor-mediated cAMP generation. J Biol Chem 279 (2004) 53036-53047
198. 2+ sensitization: rho-associated kinase-mediated phosphorylation of MYPT1 at Thr-855, but not Thr-697. Biochem J 389 (2005) 763-774
199. Wood C.E., Cudd T.A., Kane C., and Engelke K. Fetal ACTH and blood pressure responses to thromboxane mimetic U-46619. Am J Physiol 265 (1993) R858-R862
200. 2 production. Prostaglandins 26 (1983) 311-324
201. 2 analog, in hemorrhaged rats. Brain Res 1118 (2006) 43-51
202. 2 receptor agonistic activities: its antiplatelet effects in human and animal platelets. J Thromb Haemost 1 (2003) 1813-1819
203. 2 receptor-mediated signal transduction in rabbit aortic smooth muscle cells. Gen Pharmacol 26 (1995) 1489-1498
204. Yokotani K., Okada S., Nakamura K., Yamaguchi-Shima N., Shimizu T., Arai J., et al. Brain prostanoid TP receptor-mediated adrenal noradrenaline secretion and EP3 receptor-mediated sympathetic noradrenaline release in rats. Eur J Pharmacol 512 (2005) 29-35
205. Zhang S., Coso O.A., Lee C., Gutkind J.S., and Simonds W.F. Selective activation of effector pathways by brain-specific G protein β5. J Biol Chem 271 (1996) 33575-33579
206. 2 receptor activity. Mol Pharmacol 69 (2006) 1433-1440
207. Zhou H., Yan F., and Tai H.H. Phosphorylation and desensitization of the human thromboxane receptor-α by G protein-coupled receptor kinases. J Pharmacol Exp Ther 298 (2001) 1243-1251